Stock Code: Teyi Pharmaceutical Group Co.Ltd(002728) stock abbreviation: Teyi Pharmaceutical Group Co.Ltd(002728) Announcement No.: 2022030 bond Code: 128025 bond abbreviation: Teyi convertible bond
Teyi Pharmaceutical Group Co.Ltd(002728)
Announcement on the resolution of the 27th meeting of the 4th board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of directors
Teyi Pharmaceutical Group Co.Ltd(002728) (hereinafter referred to as “the company”) the 27th meeting of the Fourth Board of directors was held at 10:30 a.m. on May 4, 2022 in the company’s conference room by on-site and communication. The notice of the meeting was sent by mail or in writing on April 29, 2022. Six directors should attend the meeting, five actually attended and one entrusted to attend. The company’s supervisors and non directors and senior management attended the meeting as nonvoting delegates. The convening and convening of the meeting shall comply with the relevant provisions of the company law and the articles of association.
2、 Deliberations of the board meeting
The meeting was presided over by Chairman Xu Danqing. After deliberation, all Directors voted by means of on-site and communication, and adopted the following resolutions:
1. The proposal on temporarily replenishing working capital by using some idle raised funds of convertible bonds was deliberated and adopted
In order to effectively improve the use efficiency of the raised funds, reduce financial expenses, reduce operating costs, and safeguard the interests of the company and shareholders, on the premise of ensuring the implementation of the investment project of the raised funds of the company’s convertible corporate bonds on schedule, the company decided to use the idle raised funds of no more than RMB 100 million (accounting for 28.87% of the net raised funds of the company’s convertible corporate bonds of RMB 34635737667) to supplement the working capital temporarily. The time limit for the company to use some idle raised funds to supplement working capital temporarily is no more than 12 months from the date of handling the temporary supplement of working capital for the first time after the deliberation and approval of the board of directors, and it will be returned to the special account for raised funds after expiration.
Voting results: 6 in favor, 0 against and 0 abstention.
2. The proposal on adjusting the exercise price of 2021 stock option incentive plan was deliberated and adopted
Voting results: 5 in favor, 0 against, 0 abstention and 1 avoidance.
Mr. Chen Xiliang, the director of the company, is the incentive object of this incentive plan, avoiding the voting of this proposal, and the other five directors participated in the voting.
It is hereby announced.
Teyi Pharmaceutical Group Co.Ltd(002728) board of directors may 5, 2022
